Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.
The above information is a part of company’s filings submitted to BSE.